首页 > 最新文献

Regenerative medicine最新文献

英文 中文
Proliferation and differentiation of Wharton's jelly-derived mesenchymal stem cells on prgf-treated hydrogel scaffold. 沃顿果冻间充质干细胞在经 prgf 处理的水凝胶支架上的增殖和分化。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-11-18 DOI: 10.1080/17460751.2024.2427513
Bahareh Pourjabbar, Forough Shams, Saeed Heidari Keshel, Esmaeil Biazar

Background: To address the limitations of Cultivated Limbal Epithelial Transplantation (CLET) and the use of amniotic membrane (AM) in treating Limbal Stem Cell Deficiency (LSCD), we aimed to develop a Collagen/Silk Fibroin (Co/SF) scaffold enriched with Platelet-Rich Growth Factor (PRGF) to support the proliferation, maintenance, and differentiation of Wharton's jelly-derived mesenchymal stem cells (WJMSCs) into corneal epithelial cells (CECs).

Method: Scaffolds loaded with PRGF were evaluated through release studies, cytotoxicity assays, and cell differentiation. The proliferation and differentiation of WJMSCs and Limbal Epithelial Stem Cells (LESCs) were investigated using MTT assays, real-time PCR and immunostaining.

Results: The PRGF-loaded Co/SF scaffold significantly promoted the proliferation of both WJMSCs and LESCs in a concentration-dependent manner. Real-time PCR and immune staining revealed a significant increase in the expression of P63, ABCG2, and cytokeratin 3/12 markers in WJMSCs, a significant decrease in the expression of P63 and ABCG2, and a significant increase in the expression of cytokeratin 3/12 markers indicating successful differentiation into CECs.

Conclusion: The WJMSC cultured on PRGF-enriched Co/SF scaffold demonstrates potential as a viable alternative to conventional CLET, offering a promising strategy for corneal tissue regeneration.

背景:为了解决培养瓣上皮移植(CLET)和使用羊膜(AM)治疗瓣膜干细胞缺乏症(LSCD)的局限性、我们旨在开发一种富含血小板生长因子(PRGF)的胶原/蚕丝纤维素(Co/SF)支架,以支持沃顿果冻间充质干细胞(WJMSCs)增殖、维持和分化为角膜上皮细胞(CECs)。方法:通过释放研究、细胞毒性试验和细胞分化对负载有 PRGF 的支架进行评估。使用 MTT 检测法、实时 PCR 和免疫染色法对 WJMSCs 和 Limbal 上皮干细胞(LESCs)的增殖和分化进行了研究:结果:PRGF负载的Co/SF支架能显著促进WJMSCs和LESCs的增殖,其增殖呈浓度依赖性。实时 PCR 和免疫染色显示,WJMSCs 中 P63、ABCG2 和细胞角蛋白 3/12 标记物的表达量明显增加,P63 和 ABCG2 的表达量明显减少,细胞角蛋白 3/12 标记物的表达量明显增加,这表明它们成功分化成了 CECs:结论:在富含 PRGF 的 Co/SF 支架上培养的 WJMSC 具有替代传统 CLET 的潜力,为角膜组织再生提供了一种前景广阔的策略。
{"title":"Proliferation and differentiation of Wharton's jelly-derived mesenchymal stem cells on prgf-treated hydrogel scaffold.","authors":"Bahareh Pourjabbar, Forough Shams, Saeed Heidari Keshel, Esmaeil Biazar","doi":"10.1080/17460751.2024.2427513","DOIUrl":"10.1080/17460751.2024.2427513","url":null,"abstract":"<p><strong>Background: </strong>To address the limitations of Cultivated Limbal Epithelial Transplantation (CLET) and the use of amniotic membrane (AM) in treating Limbal Stem Cell Deficiency (LSCD), we aimed to develop a Collagen/Silk Fibroin (Co/SF) scaffold enriched with Platelet-Rich Growth Factor (PRGF) to support the proliferation, maintenance, and differentiation of Wharton's jelly-derived mesenchymal stem cells (WJMSCs) into corneal epithelial cells (CECs).</p><p><strong>Method: </strong>Scaffolds loaded with PRGF were evaluated through release studies, cytotoxicity assays, and cell differentiation. The proliferation and differentiation of WJMSCs and Limbal Epithelial Stem Cells (LESCs) were investigated using MTT assays, real-time PCR and immunostaining.</p><p><strong>Results: </strong>The PRGF-loaded Co/SF scaffold significantly promoted the proliferation of both WJMSCs and LESCs in a concentration-dependent manner. Real-time PCR and immune staining revealed a significant increase in the expression of P63, ABCG2, and cytokeratin 3/12 markers in WJMSCs, a significant decrease in the expression of P63 and ABCG2, and a significant increase in the expression of cytokeratin 3/12 markers indicating successful differentiation into CECs.</p><p><strong>Conclusion: </strong>The WJMSC cultured on PRGF-enriched Co/SF scaffold demonstrates potential as a viable alternative to conventional CLET, offering a promising strategy for corneal tissue regeneration.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"1-12"},"PeriodicalIF":2.4,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ATMP clinical trials in the UK. 英国的 ATMP 临床试验。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-11-16 DOI: 10.1080/17460751.2024.2427505
Rehma Chandaria, Philippa Rice, Daniel Baston, Finn Willingham, Jacqueline Barry

Aims: The UK advanced therapy medicinal product (ATMP) clinical trials database, produced annually by CGT Catapult, aims to assess the progress and state of the UK ATMP clinical development landscape. The aim of this article is to highlight key findings from the database and put them into context within the global landscape and various initiatives intended to attract ATMP developers to the UK.

Method: A targeted search of GlobalData's clinical trial database was performed, followed by refinement so that only trials investigating products meeting ATMP definitions were included, and that each trial was only counted once in the analysis.

Results: The 2023 data show that the number of ongoing ATMP clinical trials in the UK has remained approximately static, in contrast to a 10% reduction reported globally. Approximately 80% of these trials were commercially sponsored. Although most ATMP clinical trials are early phase, there is evidence indicating progression to later phase studies.

Conclusion: The data indicate that the UK remains an attractive region for ATMP clinical trials. Factors including UK government investment in research, regulatory support offered by MHRA, and the Advanced Therapy Treatment Centre (ATTC) network of clinical sites, may contribute to the positive ecosystem available to developers of ATMPs.

目的:英国先进治疗药物产品(ATMP)临床试验数据库由 CGT Catapult 每年编制一次,旨在评估英国 ATMP 临床开发的进展和状况。本文旨在强调该数据库的主要发现,并将其与全球形势和旨在吸引ATMP开发商来英国的各种举措结合起来:方法:对GlobalData的临床试验数据库进行了有针对性的搜索,然后进行了细化,以便只纳入研究符合ATMP定义的产品的试验,并且每项试验在分析中只计算一次:2023 年的数据显示,英国正在进行的 ATMP 临床试验数量基本保持稳定,而全球报告的数量则减少了 10%。这些试验中约有 80% 由商业赞助。尽管大多数 ATMP 临床试验都处于早期阶段,但有证据表明,后期阶段的研究也在不断进展:数据表明,英国仍然是 ATMP 临床试验的理想地区。英国政府在研究方面的投资、英国医疗药品管理局(MHRA)提供的监管支持以及先进疗法治疗中心(ATTC)的临床基地网络等因素,可能有助于为 ATMP 开发商提供积极的生态系统。
{"title":"ATMP clinical trials in the UK.","authors":"Rehma Chandaria, Philippa Rice, Daniel Baston, Finn Willingham, Jacqueline Barry","doi":"10.1080/17460751.2024.2427505","DOIUrl":"https://doi.org/10.1080/17460751.2024.2427505","url":null,"abstract":"<p><strong>Aims: </strong>The UK advanced therapy medicinal product (ATMP) clinical trials database, produced annually by CGT Catapult, aims to assess the progress and state of the UK ATMP clinical development landscape. The aim of this article is to highlight key findings from the database and put them into context within the global landscape and various initiatives intended to attract ATMP developers to the UK.</p><p><strong>Method: </strong>A targeted search of GlobalData's clinical trial database was performed, followed by refinement so that only trials investigating products meeting ATMP definitions were included, and that each trial was only counted once in the analysis.</p><p><strong>Results: </strong>The 2023 data show that the number of ongoing ATMP clinical trials in the UK has remained approximately static, in contrast to a 10% reduction reported globally. Approximately 80% of these trials were commercially sponsored. Although most ATMP clinical trials are early phase, there is evidence indicating progression to later phase studies.</p><p><strong>Conclusion: </strong>The data indicate that the UK remains an attractive region for ATMP clinical trials. Factors including UK government investment in research, regulatory support offered by MHRA, and the Advanced Therapy Treatment Centre (ATTC) network of clinical sites, may contribute to the positive ecosystem available to developers of ATMPs.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"1-8"},"PeriodicalIF":2.4,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry updates from the field of stem cell research and regenerative medicine in September 2024. 2024 年 9 月干细胞研究和再生医学领域的行业动态。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-11-15 DOI: 10.1080/17460751.2024.2427501
Dusko Ilic, Mirjana Liovic

Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in September 2024.

2024 年 9 月干细胞研究和再生医学领域的最新进展,汇编自公开信息和非学术机构的新闻稿。
{"title":"Industry updates from the field of stem cell research and regenerative medicine in September 2024.","authors":"Dusko Ilic, Mirjana Liovic","doi":"10.1080/17460751.2024.2427501","DOIUrl":"https://doi.org/10.1080/17460751.2024.2427501","url":null,"abstract":"<p><p>Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in September 2024.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"1-10"},"PeriodicalIF":2.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 更正。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-11-12 DOI: 10.1080/17460751.2024.2427474
{"title":"Correction.","authors":"","doi":"10.1080/17460751.2024.2427474","DOIUrl":"https://doi.org/10.1080/17460751.2024.2427474","url":null,"abstract":"","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"1"},"PeriodicalIF":2.4,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142626087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry updates from the field of stem cell research and regenerative medicine in August 2024. 2024 年 8 月干细胞研究和再生医学领域的行业动态。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-11-04 DOI: 10.1080/17460751.2024.2418246
Dusko Ilic, Mirjana Liovic

Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in August 2024.

2024 年 8 月干细胞研究和再生医学领域的最新进展,汇编自公开信息和非学术机构的新闻稿。
{"title":"Industry updates from the field of stem cell research and regenerative medicine in August 2024.","authors":"Dusko Ilic, Mirjana Liovic","doi":"10.1080/17460751.2024.2418246","DOIUrl":"https://doi.org/10.1080/17460751.2024.2418246","url":null,"abstract":"<p><p>Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in August 2024.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"1-7"},"PeriodicalIF":2.4,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasound-guided injection using leucocyte-rich platelet-rich plasma for treatment of meniscal injuries in a duathlete: a case report. 使用富含白细胞的血小板血浆在超声波引导下注射治疗一名双项全能运动员的半月板损伤:病例报告。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-10-30 DOI: 10.1080/17460751.2024.2418705
Jeimylo C de Castro, Daniel Wang, Paschenelle Celis, Jeffrey Strakowski

There is a paucity of data regarding using platelet-rich plasma therapy for Baker's cyst-associated medial meniscal tear. To date, conservative treatments for this type of condition include aspiration of fluid effusion with steroid injection and physical therapy. When this treatment fails, arthroscopic debridement, meniscectomy, cyst decompression and open cystectomy are available surgical management options. Recurrence rates, however, are high such that even these procedures fail to provide long-term pain relief. This case study explores the benefits of leukocyte-rich platelet-rich plasma therapy in treating tears in the posterior horn of the medial meniscus with concomitant Baker's cyst. With limited studies available, this case hopes to encourage more studies to be done in the future to provide a conservative option for patients with similar cases.

有关使用富血小板血浆疗法治疗贝克氏囊肿相关性内侧半月板撕裂的数据很少。迄今为止,治疗此类病症的保守疗法包括抽吸积液、注射类固醇和物理疗法。治疗无效时,可选择关节镜清创术、半月板切除术、囊肿减压术和开放性囊肿切除术等手术治疗方法。然而,复发率很高,即使这些手术也无法长期缓解疼痛。本病例研究探讨了富含白细胞的富血小板血浆疗法在治疗伴有贝克氏囊肿的内侧半月板后角撕裂中的益处。由于现有的研究有限,本病例希望鼓励今后开展更多的研究,为类似病例的患者提供一种保守的选择。
{"title":"Ultrasound-guided injection using leucocyte-rich platelet-rich plasma for treatment of meniscal injuries in a duathlete: a case report.","authors":"Jeimylo C de Castro, Daniel Wang, Paschenelle Celis, Jeffrey Strakowski","doi":"10.1080/17460751.2024.2418705","DOIUrl":"10.1080/17460751.2024.2418705","url":null,"abstract":"<p><p>There is a paucity of data regarding using platelet-rich plasma therapy for Baker's cyst-associated medial meniscal tear. To date, conservative treatments for this type of condition include aspiration of fluid effusion with steroid injection and physical therapy. When this treatment fails, arthroscopic debridement, meniscectomy, cyst decompression and open cystectomy are available surgical management options. Recurrence rates, however, are high such that even these procedures fail to provide long-term pain relief. This case study explores the benefits of leukocyte-rich platelet-rich plasma therapy in treating tears in the posterior horn of the medial meniscus with concomitant Baker's cyst. With limited studies available, this case hopes to encourage more studies to be done in the future to provide a conservative option for patients with similar cases.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"1-6"},"PeriodicalIF":2.4,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influencing factors and repair advancements in rodent models of peripheral nerve regeneration. 周围神经再生啮齿动物模型的影响因素和修复进展。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-10-29 DOI: 10.1080/17460751.2024.2405318
Timothy C Olsen, Jonnby S LaGuardia, David R Chen, Ryan S Lebens, Kelly X Huang, David Milek, Mark Noble, Jonathan I Leckenby

Peripheral nerve injuries lead to severe functional impairments, with rodent models essential for studying regeneration. This review examines key factors affecting outcomes. Age-related declines, like reduced nerve fiber density and impaired axonal transport of vesicles, hinder recovery. Hormonal differences influence regeneration, with BDNF/trkB critical for testosterone and nerve growth factor for estrogen signaling pathways. Species and strain selection impact outcomes, with C57BL/6 mice and Sprague-Dawley rats exhibiting varying regenerative capacities. Injury models - crush for early regeneration, chronic constriction for neuropathic pain, stretch for traumatic elongation and transection for severe lacerations - provide insights into clinically relevant scenarios. Repair techniques, such as nerve grafts and conduits, show that autografts are the gold standard for gaps over 3 cm, with success influenced by graft type and diameter. Time course analysis highlights crucial early degeneration and regeneration phases within the first month, with functional recovery stabilizing by three to six months. Early intervention optimizes regeneration by reducing scar tissue formation, while later interventions focus on remyelination. Understanding these factors is vital for designing robust preclinical studies and translating research into effective clinical treatments for peripheral nerve injuries.

周围神经损伤会导致严重的功能障碍,而啮齿动物模型对研究再生至关重要。本综述探讨了影响结果的关键因素。与年龄有关的衰退,如神经纤维密度降低和轴突运输囊泡受损,都会阻碍恢复。激素差异会影响再生,BDNF/trkB 对睾酮和神经生长因子对雌激素信号通路至关重要。物种和品系选择会影响结果,C57BL/6 小鼠和 Sprague-Dawley 大鼠表现出不同的再生能力。损伤模型--用于早期再生的挤压模型、用于神经病理性疼痛的慢性收缩模型、用于创伤性伸长的拉伸模型以及用于严重撕裂伤的横断模型--提供了对临床相关情况的深入了解。神经移植和导管等修复技术表明,自体移植是间隙超过 3 厘米的黄金标准,成功与否受移植类型和直径的影响。时间进程分析显示,第一个月内的早期退化和再生阶段至关重要,功能恢复在三到六个月内趋于稳定。早期干预通过减少瘢痕组织的形成来优化再生,而后期干预则侧重于再髓鞘化。了解这些因素对于设计强有力的临床前研究以及将研究成果转化为有效的周围神经损伤临床治疗方法至关重要。
{"title":"Influencing factors and repair advancements in rodent models of peripheral nerve regeneration.","authors":"Timothy C Olsen, Jonnby S LaGuardia, David R Chen, Ryan S Lebens, Kelly X Huang, David Milek, Mark Noble, Jonathan I Leckenby","doi":"10.1080/17460751.2024.2405318","DOIUrl":"10.1080/17460751.2024.2405318","url":null,"abstract":"<p><p>Peripheral nerve injuries lead to severe functional impairments, with rodent models essential for studying regeneration. This review examines key factors affecting outcomes. Age-related declines, like reduced nerve fiber density and impaired axonal transport of vesicles, hinder recovery. Hormonal differences influence regeneration, with BDNF/trkB critical for testosterone and nerve growth factor for estrogen signaling pathways. Species and strain selection impact outcomes, with C57BL/6 mice and Sprague-Dawley rats exhibiting varying regenerative capacities. Injury models - crush for early regeneration, chronic constriction for neuropathic pain, stretch for traumatic elongation and transection for severe lacerations - provide insights into clinically relevant scenarios. Repair techniques, such as nerve grafts and conduits, show that autografts are the gold standard for gaps over 3 cm, with success influenced by graft type and diameter. Time course analysis highlights crucial early degeneration and regeneration phases within the first month, with functional recovery stabilizing by three to six months. Early intervention optimizes regeneration by reducing scar tissue formation, while later interventions focus on remyelination. Understanding these factors is vital for designing robust preclinical studies and translating research into effective clinical treatments for peripheral nerve injuries.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"1-17"},"PeriodicalIF":2.4,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracellular vesicles for corneal regeneration: the new frontier. 用于角膜再生的细胞外囊泡:新领域。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-10-18 DOI: 10.1080/17460751.2024.2412510
Keya Jafari, Ashkon Seyed-Safi, Sajjad Ahmad
{"title":"Extracellular vesicles for corneal regeneration: the new frontier.","authors":"Keya Jafari, Ashkon Seyed-Safi, Sajjad Ahmad","doi":"10.1080/17460751.2024.2412510","DOIUrl":"https://doi.org/10.1080/17460751.2024.2412510","url":null,"abstract":"","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"1-4"},"PeriodicalIF":2.4,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry updates from the field of stem cell research and regenerative medicine in July 2024. 2024 年 7 月干细胞研究和再生医学领域的行业动态。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-10-14 DOI: 10.1080/17460751.2024.2402645
Dusko Ilic, Mirjana Liovic

Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in July 2024.

2024 年 7 月干细胞研究和再生医学领域的最新进展,汇编自公开信息和非学术机构的新闻稿。
{"title":"Industry updates from the field of stem cell research and regenerative medicine in July 2024.","authors":"Dusko Ilic, Mirjana Liovic","doi":"10.1080/17460751.2024.2402645","DOIUrl":"https://doi.org/10.1080/17460751.2024.2402645","url":null,"abstract":"<p><p>Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in July 2024.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"1-8"},"PeriodicalIF":2.4,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statement of Retraction: The first Stem Cell-Based Tissue-Engineered Organ Replacement: Implications for Regenerative Medicine and Society. 撤回声明:首例基于干细胞的组织工程器官置换术:对再生医学和社会的影响》。
IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Pub Date : 2024-10-14 DOI: 10.1080/17576180.2024.2413823
{"title":"Statement of Retraction: The first Stem Cell-Based Tissue-Engineered Organ Replacement: Implications for Regenerative Medicine and Society.","authors":"","doi":"10.1080/17576180.2024.2413823","DOIUrl":"https://doi.org/10.1080/17576180.2024.2413823","url":null,"abstract":"","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"1"},"PeriodicalIF":2.4,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Regenerative medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1